Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Peng, Jiang , Wang, Zhijun , Yan, Binyuan , Zhu, Shouhai , Huang, Zhenlin , Zhang, Jianong , Ding, Donglin , Li, Xiang , Wang, Liguo , Jin, Baiye , Pang, Jun, Xia, Dan , Sun, Rui , Yan, Binyuan , Zhu, Shouhai , Wang, Liguo , Lou, Zhenkun , Jin, Baiye , Huang, Rui , Sun, Rui , Wang, Zhijun, Lou, Zhenkun , Jin, Baiye , Pang, Jun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | July 7, 2025 | Volume: 122 | Issue: 28 | Pages: No page available

10.1073/pnas.2413732122 | PMID 40623188 Get It

CDK12 primarily functions as a transcription regulatory cyclin-dependent kinase (CDK) that controls mRNA elongation, splicing, and polyadenylation. The CDK12 gene is implicated in human cancers since it is frequently mutated and/or deleted in prostate and ovarian cancer but paradoxically amplified in breast cancer. Here, we demonstrate that CDK12 promotes serine-933 phosphorylation of DNA2, a nuclease/helicase critical for replication fork stress regulation, and the phosphorylation subsequently facilitates DNA2 polyubiquitination and degradation mediated by the APC/C CDC20 E3 ubiquitin ligase. CDK12 inactivation induces but amplification suppresses genome-wide expression of interferon response and antigen processing and presentation machinery genes in ovarian and breast cancer cells, respectively. Besides causing aberrant DNA2 stabilization, replication stress, genomic instability, and cytosolic double-stranded DNA (dsDNA) accumulation, CDK12 loss also triggers cGAS–STING activation and innate immune response, which can be reversed by forced expression of replication protein A (RPA) subunits or DNA2 depletion. Our findings identify DNA2 as a phosphorylation substrate of CDK12, connecting CDK12 to cell cycle regulation. These data also reveal DNA2 protein destruction as a critical mechanism that dictates genomic instability, cGAS–STING signaling activation, and innate immune response in CDK12-deregulated cancers.
Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

Mayo Clinic

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-<25; overweight, 25-<30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P < .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.
Recombinant herpes zoster vaccine lowers shingles complication risk in patients with inflammatory bowel disease
Wang, Yichen , Huang, Yuting , Hashash, Jana, Odah, Tarek , Caldera, Freddy, Caldera, Freddy , Caldera, Freddy , Huang, Yuting , Wang, Yichen , Hayney, Mary S. , Farraye, Francis A.

Mayo Clinic

Journal of Crohn’s and Colitis | July 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf116 | PMID 40623013 Get It

Abstract Background Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ) infection due to innate immune abnormalities and use of immunosuppressive therapy. The recombinant zoster vaccine (RZV) is recommended, but its efficacy in preventing recurrent HZ among patients with IBD is not well established. Methods Using data from the TriNetX Linked Network, we conducted a retrospective cohort study of adults (≥18 years) with IBD and a prior uncomplicated HZ episode. Patients with IBD who received RZV were propensity score-matched 1:1 with those who did not. The primary outcome was subsequent HZ complications. Secondary outcomes included subtypes of HZ complications and recurrent uncomplicated HZ. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated via Cox proportional hazards models. Results After matching, 1260 vaccinated and 1260 unvaccinated patients with IBD were included. Compared to the unvaccinated cohort, patients receiving RZV had a significantly reduced incidence of HZ complications (7.4% vs. 14.5%; HR, 0.75; 95% CI, 0.58–0.97; P = .028). Postherpetic neuralgia was notably decreased (5.8% vs. 12.5%; HR, 0.66; P = .010), and no central nervous system involvement occurred among vaccinated patients. Protective effects were more pronounced in patients with ulcerative colitis, females, and those not receiving immunosuppressive therapy. Conclusions RZV substantially lowers the risk of HZ complications in patients with IBD, offering significant clinical benefits to those at high risk due to immunosuppression. These findings underscore the importance of RZV as part of preventive care strategies in patients with IBD.
A practical guide for nephrologist peer reviewers: evaluating artificial intelligence and machine learning research in nephrology
Wang, Yanni , Cheungpasitporn, Wisit, Qing, Jianbo , Kaewput, Wisit , Soliman, Karim , Cheungpasitporn, Wisit , Kaewput, Wisit , Soliman, Karim M , Zhang, Zhongheng , Cheungpasitporn, Wisit , Ali, Hatem , Thongprayoon, Charat , Huang, Zhengxing , Yang, Min

Mayo Clinic

Renal Failure | July 7, 2025 | Volume: 47 | Issue: 1 | Pages: No page available

10.1080/0886022x.2025.2513002 | PMID 40620096 Get It

Multimodality Craniofacial Phenotyping of Congenital Facial Weakness Disorders
Almpani, Konstantinia , Devine, Kate, Mishra, Rashmi , Bassim, Carol W. , Ryzin, Carol Van, Barry, Brenda J. , Engle, Elizabeth C. , Collins, Francis S. , Manoli, Irini , Lee, Janice S. , Engle, Elizabeth C , Wang Jabs, Ethylin, Lee, Janice S , Manoli, Irini , Devine, Katelin R., Liberton, Denise K. , Facio, Flavia M. , Webb, Bryn D. , Jabs, Ethylin W

Mayo Clinic

The Cleft Palate Craniofacial Journal | July 4, 2025 | Volume: 63 | Issue: 6 | Pages: 1455-1468

10.1177/10556656251344128 | PMID 40611650 Get It

Objective Congenital facial weakness (CFW) disorders are a heterogeneous group of rare conditions, that present at birth, with reduced facial movement, and mask-like facies. This study utilized a multimodality approach to examine the craniofacial and intraoral phenotypes among CFW disorders: Moebius syndrome (MBS), Hereditary Congenital Facial Palsy (HCFP), β-tubulin isotype 3 syndrome (CFEOM3A-TUBB3), Carey-Fineman-Ziter syndrome (CFZS), and a group of rarer disorders (Other). Design Prospective cohort study. Setting: Dental clinic. Participants: Sixty individuals (sex ratio 1:1, mean age 26.2 ± 17.5 years) with a diagnosis of CFW. Interventions: Deep clinical craniofacial and dental phenotyping, three-dimensional facial surface and cone-beam computed tomography scans, and cephalometric and geometric morphometric analyses. Results CFEOM3A-TUBB3, MBS, and CFZS groups had the highest prevalence of craniofacial anomalies; HCFP individuals were least affected. CFEOM3A-TUBB3 had a higher prevalence of short lower face (75%), poor oral hygiene (100%)/decay (75%), and Class II malocclusion (87.5%). Moebius syndrome was associated with lagophthalmos (90.9%), tongue fissures (72.4%), tight/small oral orifice (51.7%), and tongue fasciculations (50%). Carey-Fineman-Ziter syndrome had oblong facial shape (100%), downward lip commissures (100%), and abnormal hearing (60%). Moderate-severe decay/gingivitis correlated with restricted oral orifice, common among patients with facial animation/sling surgery. Morphologically, the CFW cohort had a relatively small craniofacial centroid size, anthropometric measurements, and distinct craniofacial shapes for each subtype. Conclusions Congenital facial weakness can result in abnormal craniofacial development in addition to the loss of facial movement. Multimodality phenotypic characterization of CFW disorders elucidated key clinical findings and distinct craniofacial shape segregation among the different groups.
Quantifying Sample Representation in Global Pharmacogenomic Studies of Major Depressive Disorder: A Systematic Review
Jackson, Linsey , Delaney, K , Bobo, Justin , Grant, Caroline W. , Hassett, Leslie C. , Wang, Liewei , Weinshilboum, Richard M. , Croarkin, Paul E. , Moyer, Ann M. , Gentry, Melanie T. , Athreya, Arjun P. , Delaney, Karina , Hassett, Leslie C , Weinshilboum, Richard M. , Moyer, AM , Croarkin, Paul E , Gentry, Melanie T , Jackson, Linsey E

Mayo Clinic

Clinical and Translational Science | July 3, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1111/cts.70256 | PMID 40611381 Get It

ABSTRACT Major depressive disorder (MDD) is a substantial public health challenge. Pharmacogenomics (PGx), which identifies genetic variations that predict drug treatment outcomes, may have utility for clinical practice, but adequate representation of all populations is needed. As precision medicine in psychiatry moves towards the use of Artificial Intelligence (AI) and Machine Learning (ML) to predict treatment outcomes using PGx data, representation of diverse populations will be especially important in order to mitigate algorithmic bias and achieve equitable and generalizable findings. This work sought to quantify population diversity in pharmacogenomic studies of MDD through a systematic review. Data from 390 MDD antidepressant PGx studies were extracted from 5739 articles screened. Studies summarized were predominantly conducted in Europe, East Asia, and North America. Across all global studies, the study population comprised 57.3% White, 36.4% Asian, 1.7% Black, 3.5% Hispanic/Latino, and 0.1% Native American or Indigenous participants. Only sixty‐three (16.2%) studies included Black or Latino/Hispanic patients. Additionally, Black, Asian, Hispanic/Latino, and American Indian/Alaska Native populations were statistically underrepresented in U.S. study populations when compared to national census data, while Asian and Black populations were underrepresented in the United Kingdom. The overrepresentation of participants from a limited number of countries combined with the underrepresentation of Black and Hispanic/Latino populations could impact the extent to which pharmacogenomic testing and associated AI/ML‐based PGx tools could individualize antidepressant medication regimens for treating MDD.
A Microsphere-Based Sensor for Point-of-Care and Non-Invasive Acetone Detection
Pérez, Óscar Osorio , Nguyen, Ngan Anh, Denham, Landon , Hendricks, Asher, Domínguez, R. , Jeong, Eun Ju , Carvalho, Márcio S. , Lima, Mateus, Eshima, Jarrett , Yu, Nanxi , Smith, Barbara S. , Wang, Shaopeng , Kulick, Doina , Forzani, Erica , Dominguez, Rodrigo E , Smith, Barbara , Wang, Shaopeng , Perez, Oscar Osorio, Jeong, Eun Ju, Lima, Mateus

Mayo Clinic

Biosensors | July 3, 2025 | Volume: 15 | Issue: 7 | Pages: 429

10.3390/bios15070429 | PMID 40710079 Get It

Ketones, which are key biomarkers of fat oxidation, are relevant for metabolic health maintenance and disease development, making continuous monitoring essential. In this study, we introduce a novel colorimetric sensor designed for potential continuous acetone detection in biological fluids. The sensor features a polydimethylsiloxane (PDMS) shell that encapsulates a sensitive and specific liquid-core acetone-sensing probe. The microsphere sensors were characterized by evaluating their size, PDMS shell thickness, colorimetric response, and sensitivity under realistic conditions, including 100% relative humidity (RH) and CO2 interference. The microsphere size and sensor sensitivity can be controlled by modifying the fabrication parameters. Critically, the sensor showed high selectivity for acetone detection, with negligible interference from CO2 concentrations up to 4%. In addition, the sensor displayed good reproducibility (CV < 5%) and stability under realistic storage conditions (over two weeks at 4 °C). Finally, the accuracy of the microsphere sensor was validated against a gold standard gas chromatography-mass spectrometry (GC-MS) method using simulated and real breath samples from healthy individuals and type 1 diabetes patients. The correlation between the microsphere sensor and GC-MS produced a linear fit with a slope of 0.948 and an adjusted R-squared value of 0.954. Therefore, the liquid-core microsphere-based sensor is a promising platform for acetone body fluid analysis.
In-vivo human gracilis muscle active force-length relationship is explained by the sliding filament theory
Wang, Zheng , Lieber, Richard L. , Binder‐Markey, Benjamin I. , Kaufman, Kenton R.

Mayo Clinic

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0704 Get It

WITHDRAWN
Defining cervical spondylotic myelopathy surgical endotypes using comorbidity clustering: a Quality Outcomes Database cervical spondylotic myelopathy study
Howell, Harrison, Mummaneni, Praveen V., Chou, Dean , Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I., Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Yen, Chun-Po , Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Haid, Regis W., Chan, Andrew K. , Howell, Harrison J. , Howell, Harrison , Yang, Eunice, Mummaneni, Praveen V. , Shaffrey, Christopher I. , Park, Paul , Uribe, Juan S.

Mayo Clinic

Neurosurgical Focus | July 1, 2025 | Volume: 59 | Issue: 1 | Pages: E4

10.3171/2025.4.focus25207 | PMID 40591975 Get It

OBJECTIVE Coexisting medical conditions are increasingly prevalent in surgical populations. The impact of multiple comorbidities on patient-reported outcomes (PROs) and endotypes of frequently co-occurring conditions for cervical spondylotic myelopathy (CSM) remain unclear. This study explores whether CSM patients with multimorbidity have worse baseline and postoperative PROs and less functional improvement after surgery compared to those with few or no comorbidities. The authors also investigated whether distinct comorbidity endotypes exist among CSM surgical patients and whether they influence postoperative outcomes. METHODS The prospective Quality Outcomes Database (QOD) was used to assess patients undergoing surgery for CSM. Multimorbidity was defined as ≥ 2 chronic conditions, including diabetes, coronary artery disease, peripheral vascular disease, arthritis, chronic renal disease, chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, depression, and anxiety. Baseline characteristics and 24-month PROs were assessed across multiple-comorbidity status, including modified Japanese Orthopaedic Association (mJOA), Neck Disability Index (NDI), visual analog scale for neck and arm pain, EQ-5D, and patient satisfaction scores. Clusters were identified from the full cohort using k-medoids, revealing subgroups with similar comorbidity endotypes. RESULTS The final cohort included 1141 CSM patients (83.1% reaching 24-month follow-up), with 761 (66.7%) having 0 or 1 comorbidity and 380 (33.3%) ≥ 2 comorbidities. The multimorbidity cohort was older (mean age 62.6 ± 11.2 vs 59.5 ± 12.0 years, p < 0.001), more likely to be female (52.9% vs 44.7%, p = 0.011), and had a higher BMI (mean 31.1 ± 6.7 vs 29.7 ± 6.2 kg/m 2 , p < 0.001). Multimorbidity patients exhibited worse mJOA, NDI, and EQ-5D scores at baseline and 24 months (p < 0.05). On multivariable analysis, the total number of comorbidities was not significantly associated with any PRO measures. Four comorbidity clusters were identified: low burden, arthritis, diabetes, and high burden. On one-way ANOVA, the baseline mJOA score was significantly different across clusters (p = 0.003). At 24 months, the mJOA score was significantly lower in the diabetes and high-burden endotypes. Twenty-four-month score change and minimal clinically important difference (MCID) achievement of all PROs remained similar across clusters (p > 0.05). CONCLUSIONS While patients with multimorbidity have worse baseline and postoperative PROs, they achieve similar functional and pain-related improvements following CSM surgery. Similarly, the comorbidity endotypes identified in this QOD cohort suggest that certain patterns of coexisting chronic conditions, such as overlapping diabetes and arthritis, are associated with different levels of disability but may not diminish the effectiveness of surgical intervention.